Today is President Biden’s 155th day in office, and he has yet to pick someone to run the U.S. Health Resources and Services Administration (HRSA), the federal agency responsible for the 340B drug pricing program.
This normally might be a handicap for HRSA, especially given that it is embroiled in multiple high-stakes lawsuits with drug manufacturers over 340B contract pharmacy. But highly competent temporary leadership at HRSA, plus the close attention 340B is getting from the White House and the U.S. Health and Human Services Department (HHS), makes the vacancy at the top of HRSA’s organizational chart less of a problem, a 17-year veteran of HRSA says.
Today is President Biden’s 155th day in office, and he has yet to pick someone to run the U.S. Health Resources and Services Administration (HRSA), the federal agency responsible for the 340B drug pricing program.
This normally might be a handicap for HRSA, especially given that it is embroiled in multiple high-stakes lawsuits with drug manufacturers over 340B contract pharmacy. But highly competent temporary leadership at HRSA, plus the close attention 340B is getting from the White House and the U.S. Health and Human Services Department (HHS), makes the vacancy at the top of HRSA’s organizational chart less of a problem, a 17-year veteran of HRSA says.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
